Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. PTN
PTN logo

PTN Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Palatin Technologies Inc (PTN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
22.380
1 Day change
-0.53%
52 Week Range
31.000
Analysis Updated At
2026/04/17
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Palatin Technologies Inc (PTN) is not a strong buy for a beginner, long-term investor at this moment. While the technical indicators show some bullish momentum, the lack of significant trading trends, weak financial performance, and absence of positive catalysts make it unsuitable for immediate investment.

Technical Analysis

The MACD histogram is positive and expanding (0.27), indicating bullish momentum. The RSI is neutral at 62.407, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key resistance levels are R1: 21.253 and R2: 22.347, with support at S1: 17.71 and S2: 16.615. However, the stock's trend suggests a 70% chance of minor declines (-0.28%) in the next day and mixed performance over the next month.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
4
Buy
9

Positive Catalysts

  • No significant positive catalysts identified. Technical indicators show some bullish momentum, but no news or event-driven catalysts are present.

Neutral/Negative Catalysts

  • Weak financial performance with declining EPS (-51.69% YoY) and negative net income (-$7,263,861). No significant hedge fund or insider trading trends. No recent congress trading data or influential figure activity.

Financial Performance

In Q2 2026, revenue remained flat at $116,036 (0.00% YoY growth). Net income improved by 197.40% YoY but remains negative at -$7,263,861. EPS dropped significantly to -2.86 (-51.69% YoY). Gross margin stayed at 100% but did not grow.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target changes available for review.

Wall Street analysts forecast PTN stock price to rise
1 Analyst Rating
Wall Street analysts forecast PTN stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 22.500
sliders
Low
50
Averages
50
High
50
Current: 22.500
sliders
Low
50
Averages
50
High
50
Laidlaw
NULL -> Buy
initiated
$60
AI Analysis
2025-12-12
Reason
Laidlaw
Price Target
$60
AI Analysis
2025-12-12
initiated
NULL -> Buy
Reason
Laidlaw initiated coverage of Palatin with a Buy rating and $60 price target. Palatin (PTN) is a clinical stage biotech company focusing on developing melanocortin receptor based therapeutics, the analyst tells investors in a research note. The firm believes the company's offerings are better than Rhythm Pharmaceuticals' (RYTM) setmelanotide and are very competitive against their next generation follow-on products.
Jefferies
Buy
downgrade
$21 -> $20
2025-12-11
Reason
Jefferies
Price Target
$21 -> $20
2025-12-11
downgrade
Buy
Reason
Jefferies lowered the firm's price target on Pattern Group to $20 from $21 and keeps a Buy rating on the shares. The firm recommends staying selective across Internet stocks, as incremental investments could limit margin expansion and concerns around AI disintermediation could limit multiple appreciation, the analyst tells investors in the firm's "2026 Internet Playbook" note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for PTN
Unlock Now

People Also Watch